Evidence map›Paper›PMID 21474585›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011

Combating antimicrobial resistance: policy recommendations to save lives.

Infectious Diseases Society of America (IDSA), Brad Spellberg, Martin Blaser, Robert J Guidos, Helen W Boucher, John S Bradley, Barry I Eisenstein, Dale Gerding, Ruth Lynfield, L Barth Reller and 5 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 325 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
325citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02046512 phase4completednot on this mapstarted 2014, after this paper: background citation

Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health

TypeinterventionalSponsorWashington University School of MedicineRan2014 to 2018Enrolled89ConditionsCommunicable Diseases, Infection, Anti-Infective Agents, Therapeutic UsesArmsProbiotic, Placebo
NCT03646227 completednot on this mapstarted 2016, after this paper: background citation

Multi-Drug Resistant Organism Network - MDRO Network

TypeobservationalSponsorDuke UniversityRan2016 to 2020Enrolled6,496ConditionsInfections Resistant to Multiple Drugs, Bacterial InfectionsArmsStandard of Care
3 · Its place in the literature

Who cites it

325 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Systematic review of multidrug-resistantFrontiers in microbiology · 2025
    Pooled it
  2. Pooled it
  3. Income level and antibiotic misuse: a systematic review and dose-response meta-analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2022
    Pooled it
  4. Real-world use of ceftolozane/tazobactam: a systematic literature review.Antimicrobial resistance and infection control · 2021
    Pooled it
  5. Antibiotic use in Brazilian hospitals in the 21st century: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2021
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

265 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Infectious Diseases Society of America (IDSA)
Brad Spellberg
Martin Blaser
Robert J Guidos
Helen W Boucher
John S Bradley
Barry I Eisenstein
Dale Gerding
Ruth Lynfield
L Barth Reller
John Rex
David Schwartz
Edward Septimus
Fred C Tenover
David N Gilbert

Funding

Mechanisms of Als vaccine protection against S. aureusR01AI072052 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SPELLBERG, BRAD J · 2007 to 2011
$1.8M
Activated Targeted Killer (ATAK) Cells for Invasive Fungal InfectionsR01AI081719 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SPELLBERG, BRAD J · 2009 to 2013
$1.7M
NIAID NIH HHS R01 AI072052NIAID NIH HHS R01 AI081719
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsBacteriaBacterial InfectionsDrug UtilizationGuidelines as TopicHealth PolicyHumansUnited StatesAnti-Bacterial Agents

Identifiers

PMID21474585
PMCPMC3738230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.